Meropenem

Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death. In August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of meropenem and [DB12107] and is intravenously admininstered. The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria. It is grouped under the following drug class(es): Beta-lactams and Carbapenems. Its therapeutic use is listed as anti-infectives, antibacterials and antibiotics. The directory classifies it as a commercial API with a semi-synthetic source/manufacturing origin. Other names for this substance include Meropenem anhydrous and Meropenemum. Its PubChem CID is 441130.